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mended threshold of willingness-to-pay (£20,000 per QALY) in conjunction with 
the costs of each route to report the incremental net monetary benefits (INB) of 
nutritional support via PN versus EN. Results: Mean QoL at 90-days and one year 
was similar between the randomised groups. At one year, the PN group had higher 
costs (£1,580 [95% CI -£792 to £3,951]), similar QALYs (0.013 [95% CI -0.014 to 0.040]) 
and negative INB (-£1,320 [95% CI -£3,709 to £1,069]) compared to the EN group. 
When a lifetime time horizon is taken, the INB of PN was positive but with con-
siderable uncertainty surrounding the result (£440 [95% CI -£3,586 to £4,466]). The 
probabilities that PN is more cost effective were 14% (1 year) and 58% (lifetime), 
respectively. ConClusions: For critically ill adult patients, providing nutritional 
support via PN versus EN is unlikely to be cost-effective. However, it should be 
recognised that considerable uncertainty surrounds the cost-effectiveness results, 
especially when projected over the patient’s lifetime.
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objeCtives: Japanese government is now trying to introduce cost-effectiveness 
analysis into its healthcare system because of severe budget constraint. It would 
be important to elucidate the basic attitude of physicians towards health care 
resource allocation on this occasion. Methods: A web-based survey for physi-
cians was carried out in Japan, adjusting for age, sex, specialty, and hospital scale, 
between February and March in 2015. The questionnaire consisted of two main 
inquiries and related questions. The 1st question was about medical decision to 
choose between two screening test for a population at low risk for colon cancer. 
Test A was more cost effective than test B, but was too expensive to be given to 
everyone in the population. The option 1 was that all subjects received test B and 
subsequently the death of 1,000 people was prevented, while the option 2 was that 
a half of the subjects were selected by lottery and received test A, preventing the 
death of 1,100 people as a consequence. The 2ndquestion was concerning prior-
ity setting between two types of diseases differing the treatment cost(disease A: 
¥10 million per patient; disease B: ¥2 million per patient). The physicians were 
asked to choose some possible combinations of numbers of people treated if the 
total expenditure were limited to 100 million yen. Results: Out of 1,089(male/
female= 891/198) respondents, 699 chose the option 1 in the 1st question. In 
question 2, 187 chose the least utilitarian combination(A;8, B;10), 125 chose 2nd 
combination(A;6, B;20), 277 chose 3rd one(A;4, B;30), 76 chose 4thone(A;2, B;40), and 
424 chose the most utilitarian option(A;0, B;50). ConClusions: We investigated 
the basic attitude of physicians towards healthcare resource allocation in Japan 
in a setting of budget constraints, which revealed that fairly extreme utilitarian 
selection was the more popular among them than expected.
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objeCtives: The Turkish Medicines and Medical Devices Agency (TMMDA) gives 
permission of unlicensed medicine use by patient basis. Authorized wholesalers 
including Turkish Pharmacists’ Association (TPA) can import the drugs based on 
the TMMDA’s permission. These medicines are reimbursed by the Social Security 
Institution (SSI), the main reimbursement agency in Turkey Until 2014 when wholesal-
ers were also authorized, pharmaceuticals under this status could only be imported 
by the Turkish Pharmacists’ Association (TPA). The aim of this study is to understand 
the trends in unlicensed medicine consumption between 2011 and 2013 when the 
TPA was the only authorized supplier. Methods: Consumption data of the top 100 
imported unlicensed medicines with the highest sales share in total expenses of 
imported off-label use was taken from the TMMDA computer database. Descriptive 
analysis was conducted. Results: The analysis showed that cost of the top 100 
imported unlicensed medicines increased in every year from 232 billion TL to 747 
billion TL between 2011 and 2013, respectively. According to the ATC code, L group 
(Antineoplastic and immunomodulating agents) had the highest number of active 
ingredients in top 100. In addition to this, the number of L group medicines rose from 
37 to 55 between 2011 and 2013. Also the average cost per box increased from 2.837 
TL to 5.308 TL in the same period. ConClusions: The cost of imported unlicensed 
medicines use increased every year in Turkey. Some cost-containment measures 
(especially for antineoplastic medicines) should be taken to reduce this cost without 
risking the patients’ access to innovative medicines.
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objeCtives: To determine the disease focus of all papers indexed in the PubMed 
database that reported costs or resource use as an outcome and were published 
in 2014. Methods: An evidence surveillance process was established based on a 
systematic search of PubMed, using key words relevant to the costs or resource use 
associated with healthcare or disease and limited to studies published in English, 
in humans, with abstracts, and either clinical trials or observational, comparative 
or multicentre studies. The surveillance incorporated all studies published from 
2010 and was updated weekly. Abstracts identified by the search of studies that 
reported data on economic burden outcomes were indexed according to disease 
area, using the chapter categorisation from ICD-10 as a framework. To account 
able fee for a given procedure) and obstetricians/gynecologists (+31.9%), while the 
lowest rates of surcharges were billed by nephrologists (< +1%) and pulmonologists 
(+3.0%). ConClusions: This study confirms that Open DAMIR data can provide a 
more nuanced estimation of the cost of certain care services than is commonly used 
for health economic evaluation in France. While the publication of this database 
represents a step forward, the inclusion of select additional variables to the database 
would further increase its usefulness in health economic assessment.
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objeCtives: Entering the fiscal adjustment program in 2010, one of the primary 
mandates for Greece was to reduce public pharmaceutical expenditure from the then 
current 2.2% of GDP to 1%. Within this context, a series of policies (increased copay-
ments, price-cuts, delisting, rebates, clawbacks etc) were enforced. As a result, 2014 
public pharmaceutical expenditure did reach 1% of GDP, but following a significant 
increase in private spending. In this light, the purpose of this study is to investigate 
the macroeconomic trends in pharma expenditure during 2009-2014 and estimate 
the public/private mix of contributions. Methods: Aggregate data on outpatient 
sales by the Greek National Medicines Agency for 2009-2014, formed the basis of the 
analysis. To account for price changes, expenditures were adjusted to 2014 constant 
prices, by estimating and using the weighted average price/box for 2014 as deflator. 
Expenditures were allocated to public or private payers according to official macro-
economic reports of the third-party payers for 2009 and via publicly available subac-
counts for 2014. Results: Pharmaceutical expenditure totaled 6.12 billion euros in 
2009 (€ 5.1 billion public, € 0.09 billion rebates, € 0.91 billion private) and € 3.57 billion 
in 2014 (€ 2 billion public expenditure, € 428 million in rebates/clawbacks, € 1.14 billion 
private). Average price per box sold fell by 36.2% during 2009-2014. Thus, when adjust-
ing for prices, the respective figures are € 3.90 and € 3.57 billion. Public/private mix was 
85%/15% for 2009 and 64%/36% for 2014 (excluding rebates). A total of a € 0.93 billion 
shift towards patients and companies (€ 564million towards patients and € 366million 
as additional rebates/clawbacks) resulted in achieving the fiscal target of 1% of GDP 
for 2014 public pharma expenditure. ConClusions: Despite the rhetoric and the 
reforms implemented, total outpatient pharmaceutical volumes dropped by only 8% 
during 2009-2014. Fiscal adjustment was achieved by cost-shifting to private payers, 
primarily to patients, raising concerns about equity in access and social solidarity.
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objeCtives: To study the direct costs of drug-related morbidity using three 
sources of data; experts opinion, medical records and survey responses from the 
general public. Methods: Probabilities for clinical outcomes of drug-related mor-
bidity were estimated based on expert opinions from 29 pharmacists and 19 phy-
sicians. Costs were assigned using Cost Per Patient register data to resource-use 
from drug-related morbidity identified in the medical records of 4970 randomly 
selected individuals from a Swedish county during a three-month study period. A 
postal survey was sent to a random sample of the Swedish population. Resource-
use resulting from drug-related morbidity reported during one month by 7099 
survey respondents, and by the expert panels, were assigned unit costs based 
on national costs statistics. All cost estimates were prevalence-based. Results: 
The expert panels reported drug-related morbidity to be common, and to cause 
considerable healthcare resource use representing up to 20% of all costs to the 
healthcare system. Drug-related morbidity identified in medical records were 
estimated to cause 1.5% of all drug costs and 9.5% of healthcare costs, and costs 
occurred in all parts of the healthcare system. According to survey responses, two 
types of drug-related morbidity - adverse drug reactions and sub-therapeutic effect 
of medication therapy - caused 0.5% of all drug costs and 6.1% of all healthcare 
costs. In addition, respondents reported informal care, lost leisure time, and sick-
leave resulting from drug-related morbidity which were unfeasible to assign costs 
in these studies. ConClusions: Based on these results, drug-related morbidity 
causes considerable resource use and harm in the general public, and throughout 
the healthcare system; in primary care, other outpatient care and inpatient care. 
Moreover, it appears that there are additional resource use due to drug-related 
morbidity, such as productivity loss, which should be included for a full account 
of the economic impact of drug-related morbidity.
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objeCtives: Early and appropriate nutritional support is recommended for criti-
cally ill patients. Evidence is conflicting regarding the optimum route of deliv-
ery and robust cost-effectiveness evidence is lacking. The objective of the study 
was to evaluate the cost-effectiveness of early nutritional support via the par-
enteral (PN) versus the enteral (EN) route in critically ill adults. Methods: We 
undertook a cost-effectiveness analysis (CEA) using data from a large, pragmatic, 
multi-centre RCT that recruited patients from 33 English adult, general critical 
care units. Resource use and outcome data on 2388 trial patients were used to 
report cost-effectiveness at 90-days and at one year, and to project lifetime cost-
effectiveness. The CEA used information on Health-related Quality of Life (QoL) 
at 90-days and at one year combined with information on vital status to report 
Quality-Adjusted Life Years (QALYs). Each QALY was valued using the NICE recom-
